Want to see GENB full AI Analyst Report?
GENB Stock Chart & Stats
$12.45
--
Market closed
$12.45
--
Day’s Range― - ―
52-Week Range$11.00 - $18.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.79B
Enterprise Value$1.72B
Total Cash (Recent Filing)$516.64M
Total Debt (Recent Filing)$65.57M
Price to Earnings (P/E)―
Beta0.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,192,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue238.77
Enterprise Value/Gross Profit436.57
Enterprise Value/Ebitda-28.35
Forecast
1Y Price Target
$25.25Price Target Upside102.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform-driven DiscoveryGenerate’s AI and computational protein-engineering platform is a durable business asset: it enables repeatable candidate generation across disease areas, shortens discovery cycles, and creates a data-based moat that can scale with more targets and partnerships over months to years.
Top-line TractionSequential revenue growth demonstrates early commercial or collaboration progress and validates parts of the platform. Stable or accelerating revenue can fund R&D collaborations and signal customer adoption that supports medium-term investment and partnership expansion.
High Gross MarginsA 100% reported gross margin implies minimal direct COGS, consistent with a software/engineered-biologics model. If sustained, incremental revenue is less encumbered by production costs, improving operating leverage potential as collaborations and licensing scale over the next several quarters.
Bears Say
Widening Net LossesNet losses far exceed revenue, indicating the business is not cash-generative and relies on external funding. Persistent large operating deficits compress runway, increase financing risk, and can force strategic trade-offs that impede product development or commercialization over the medium term.
Substantial Cash BurnOperating and free cash flow closely track large net losses, showing losses translate into real cash outflows. This creates ongoing funding needs, heightens dilution or debt risk, and undermines long-term execution unless cash generation improves or new capital is secured.
Negative Equity And Shrinking AssetsDeeply negative shareholders’ equity and materially lower assets weaken financial flexibility and limit traditional borrowing. This structural balance-sheet weakness raises insolvency and covenant risk under stress and can constrain strategic options over a multi-quarter horizon.
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $18.18 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Generate Biomedicines, Inc.’s market cap is $1.79B.
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 128,192,490 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generate Biomedicines, Inc. Stock Smart Score
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
GENB Stock 12 Month Forecast
Average Price Target
$25.25
▲(102.81% Upside)
Zymeworks
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
AbSci
―
Eikon Therapeutics, Inc.
―
Ownership Overview
52.07% Insiders
<0.01% Mutual Funds
0.18% Other Institutional Investors
44.68% Public Companies and
Individual Investors